NCT00312039View on ClinicalTrials.gov

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
HIV Infections
Interventions
DRUG

Elvucitabine

Elvucitabine 10 mg QD for 14days

DRUG

Lamivudine

Lamivudine 300 mg QD for 14 days

Trial Locations (8)

10003

Clinical Trial Site, New York

30308

Clinical Trial Site, Atlanta

32803

Clinical Trial Site, Orlando

33136

Clinical Trial Site, Miami

33401

Clinical Trial Site, West Palm Beach

35294

Clinical Trial Site, Birmingham

45242

Clinical Trial Site, Cincinnati

95817

Clinical Trial Site, Sacramento

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY